Imaging of β-cell mass and function

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1001-1004

  Ichise, Masanori ^a   Harris, Paul E ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Beta cell mass; Diabetes; DTBZ; Pancreas; PET; VMAT2

Indexed keywords

4 FLUOROBENZYLTROZAMICOL F 18; ACETIC ACID C 11; BIOLOGICAL MARKER; DIHYDROTETRABENAZINE C 11; DOPA; DOPAMINE 2 RECEPTOR; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROPROPYL DIHYDROTETRABENAZINE C 11; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INDIUM 111; INSULIN; IODINE 123; PANCREAS POLYPEPTIDE; RADIOISOTOPE; RADIOLIGAND; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; SLC18A2 PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER;

APOPTOSIS; CELL FUNCTION; CELL KINETICS; CELL REGENERATION; CELL VOLUME; DRUG HALF LIFE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULAR IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PANCREAS ISLET BETA CELL; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; DIABETES MELLITUS; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; ULTRASTRUCTURE;

BIOLOGICAL MARKERS; DIABETES MELLITUS; HUMANS; INSULIN-SECRETING CELLS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 77954988574     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.068999     Document Type: Review

References (36)

1. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005;48:2221-2228.
2. Matveyenko AV, Butler PC. Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab. 2008;10(suppl 4):23-31.
3. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U. S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32:287-294.
4. Brandenburg D. History and diagnostic significance of C-peptide. Exp Diabetes Res. 2008:576862.
5. Medvei VC. The History of Clinical Endocrinology. Carnforth, Lancashire, U. K.: Parthenon Publishing Group; 1993:16.
6. Medarova Z, Moore A. MRI as a tool to monitor islet transplantation. Nat Rev Endocrinol. 2009;5:444-452.
7. Shreve PD, Gross MD. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med. 1997;38:1305-1310.
8. Toso C, Zaidi H, Morel P, et al. Positron-emission tomography imaging of early events after transplantation of islets of Langerhans. Transplantation. 2005;79:353-355.
9. Clark PB, Plaza MJ, Kraas J, et al. Dual radiotracer analysis of cholinergic neuronal changes in prediabetic mouse pancreas. Diabetes Technol Ther. 2009;11:107-111.
10. Maffei A, Harris PE. Targeting vesicular monoamine transporter type 2 for noninvasive PET-based β-cell mass measurements. Expert Rev Endocrinol Metab. 2007;2:35-46.
11. 11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab. 1996;16:1288-1299.
12. Anlauf M, Eissele R, Schafer MK, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem. 2003;51:1027-1040.
13. Ericson LE, Hakanson R, Lundquist I. Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA: localization to secretory granules and inhibition of insulin secretion. Diabetologia. 1977;13:117-124.
14. Raffo A, Hancock K, Polito T, et al. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine. J Endocrinol. 2008;198:41-49.
15. Rubi B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem. 2005;280:36824-36832.
16. 11C]DTBZ. Nucl Med Biol. 2006;33:855-864.
17. Souza F, Simpson N, Raffo A, et al. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest. 2006;116:1506-1513.
18. Cline G, Carson RE, Ding YS, et al. Islet-selectivity of G-protein coupled receptor (GPCR) ligands evaluated for PET imaging [abstract]. Diabetes. 2008;58(suppl):156.
19. Kung M, Lieberman B, Hou C, et al. F-18 (+) FP-DTBZ: an investigational PET ligand for measuring beta cell mass in the pancreas [abstract]. J Nucl Med. 2007;48(suppl):114P.
20. Singhal T, Labaree D, Ropchan J, et al. Evaluation of [C-11]DTBZ-PET for estimation of pancreatic beta cell mass (BCM) in a rat model of diabetes [abstract]. J Nucl Med. 2008;49(suppl):317P.
21. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med. 2009;50:382-389.
22. Saisho Y, Harris PE, Butler AE, et al. Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol. 2008;39:543-551.
23. Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia. 1983;24:366-371.
24. Herrera PL. Defining the cell lineages of the islets of Langerhans using transgenic mice. Int J Dev Biol. 2002;46:97-103.
25. 18F-FP-DTBZ enantiomers [abstract]. J Nucl Med. 2009;50(suppl):227P.
26. Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 2006;33:685-694.
27. 18F epoxide derivative of tetrabenazine. Nucl Med Biol. 2008;35:825-837.
28. Goodison S, Kenna S, Ashcroft SJ. Control of insulin gene expression by glucose. Biochem J. 1992;285:563-568.
29. Wang H, Kouri G, Wollheim CB. ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. J Cell Sci. 2005;118:3905-3915.
30. Moore A. Advances in beta-cell imaging. Eur J Radiol. 2009;70:254-257.
31. Antkowiak PF, Tersey SA, Carter JD, et al. Noninvasive assessment of pancreatic beta-cell function in vivo with manganese-enhanced magnetic resonance imaging. Am J Physiol Endocrinol Metab. 2009;296:E573-E578.
32. Maffei A, Liu Z, Witkowski P, et al. Identification of tissue-restricted transcripts in human islets. Endocrinology. 2004;145:4513-4521.
33. 18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism. Horm Res. 2008;70:65-72.
34. Moore A, Bonner-Weir S, Weissleder R. Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes. 2001;50:2231-2236.
35. Gotthardt M, Lalyko G, van Eerd-Vismale J, et al. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept. 2006;137:162-167.
36. Mukai E, Toyoda K, Kimura H, et al. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem Biophys Res Commun. 2009;389:523-526.